Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

NEW YORK , April 9, 2026 /PRNewswire/ --  Lucid Diagnostics Inc.   (Nasdaq: LUCD)  ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D. , Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 25 ^th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT.

The fireside chat will be webcast live and available via the Investor Relations Section of the Lucid Diagnostics website or by clicking here .  A replay of the webcast will be archived on the website for 30 days following the live event.

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ^® Esophageal DNA Test , performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ^® Esophageal Cell Collection Device , represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com .

View original content to download multimedia: https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference-302736626.html

SOURCE Lucid Diagnostics